A new feasibility study from the National University of Natural Medicine (NUNM) explored a novel, group-based model of psilocybin-assisted therapy for low-income adults with depression.
Promising Outcomes
The LIGPATD (Low-Income Group Psilocybin Assisted Therapy for Depression) study, led by Dr. Matthew Hicks and conducted through NUNM’s Helfgott Research Institute, involved 19 Medicaid-eligible participants split into four small cohorts.
Over the course of a one-month program—including psilocybin sessions followed by group integration—many participants reported significant improvements in depression symptoms as well as measurable improvements in anxiety, sleep quality, fatigue, and cognitive function.
Participants also described profound experiences of emotional release, spiritual insight, and interpersonal connection. Satisfaction was high, and the dropout rate was notably low, suggesting effective engagement and feasibility.
The group format also helped reduce practical barriers to access: it held therapeutic benefits while being more cost-efficient and scalable than traditional one-on-one models.
Group vs. Individual Psilocybin Journeys
At Vital Reset, we offer both group and individual psilocybin experiences. Most of the scientific research to date—including the largest and most rigorous studies—has been done with one-on-one facilitation, where the full attention of a facilitator is available for each participant. Many clients value that individual focus, especially if they have complex histories, emotional sensitivities, or a desire for deep personal exploration.
Group experiences, like those in the NUNM study, can provide a strong sense of connection and shared understanding, but they also carry some limitations. A single participant in distress can shift the group’s energy, and facilitator attention must be divided. In our own experience, group journeys often work best for people who are comfortable in shared settings and who value community as part of their healing process.
The NUNM study shows that group-based psilocybin can still produce meaningful benefits for depression, but for some individuals—particularly those seeking very personal or intensive support—one-on-one facilitation may be the better fit.
A Case for Feasibility, Not Definitive Proof
While the results are inspiring, important limitations must be addressed:
-
Small Sample Size: The study involved just 19 participants, far too few to generalize widely.
-
Feasibility Focus: The primary aim was to assess practicality, acceptability, and safety—not to prove clinical efficacy.
-
No Control Group: Without a comparison group, we can’t separate psilocybin’s effects from placebo or group support.
-
Short-Term: The study lasted one month, with a three month follow up period. Long-term results are unknown.
-
Specific Population: Focused on low-income adults in Oregon, limiting applicability elsewhere.
Context: Early but Encouraging
This study adds to a growing body of research suggesting psilocybin may offer meaningful relief for depression. However, most studies so far—including this one—are small, preliminary, and short-term. Larger randomized controlled trials are needed to confirm these findings and explore the durability of benefits.
Final Thoughts
The NUNM group study stands out for its focus on equity and accessibility in mental health care. The group-based approach is innovative and could make psychedelic therapy more affordable and scalable. But as with all early research, these results should be viewed as encouraging but not conclusive.
At Vital Reset, we’re encouraged by these findings and remain committed to offering both individual and group psilocybin experiences—helping clients choose the format that best supports their goals for healing and transformation.
